Glioblastoma is the most common malignant primary central nervous system tumor and one
of the most debilitating cancers. The prognosis of patients with glioblastoma remains poor …

Tremendous success using CAR T therapy in hematological malignancies has garnered
significant interest in developing such treatments for solid tumors, including brain tumors …

A great progress has been made in the development and use of lab-on-a-chip devices to
model and study the blood–brain barrier (BBB) in the last decade. We present the main …

Metastatic brain cancer has poor prognosis due to challenges in both detection and
treatment. One contributor to poor prognosis is the blood–brain barrier (BBB), which …

The complex structure of the blood–brain barrier (BBB), which blocks nearly all large
biomolecules, hinders drug delivery to the brain and drug assessment, thus decelerating …

Glioblastoma (GBM) is the most malignant type of primary intracranial tumor with a median
overall survival of only 14 months, a very poor prognosis and a recurrence rate of 90%. It is …

Adoptive chimeric antigen receptor (CAR) T cells designed to recognize specific tumor
antigens have shown promising results in cancer therapy. While CAR T cell therapy has …

The effect of chemotherapy for anti-glioblastoma is limited due to insufficient drug delivery
across the blood–brain–barrier. Poloxamer 188-coated nanoparticles can enhance the …

Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median
overall survival of less than 2 years and a nearly 100% mortality rate under standard therapy …

Blood–brain barrier (BBB) dysfunction is a key feature in neuroimmunological and
neurodegenerative diseases. In this study, we developed a microfluidic human BBB-on-a …